We analyzed the safety and efficacy of Mylotarg (gemtuzumab ozogamicin, an antibody-targeted chemotherapy consisting of a humanized anti-CD33 antibody linked to calicheamicin, a potent antitumor antibiotic) in the treatment of 101 patients Ն60 years of age with acute myeloid leukemia (AML) in untreated first relapse in three open-label trials. Mylotarg is administered as a 2-h intravenous infusion at 9 mg/m 2 for two doses with 14 days between doses. The overall remission rate was 28%, with complete remission (CR) in 13% of patients and complete remission with incomplete platelet recovery (CRp) in 15%. Median survival was 5.4 months for all patients and 14.5 months and 11.8 months for patients achieving CR and CRp, respectively. CD33 antigen is present on normal hematopoietic progenitor cells; thus, an expected high incidence of grade 3 or 4 neutropenia (99%) and thrombocytopenia (99%) was observed. The incidences of grade 3 or 4 elevations of bilirubin and hepatic transaminases were 24% and 15%, respectively. There was a low incidence of grade 3 or 4 mucositis (4%) and infections (27%) and no treatment-related cardiotoxicity, cerebellar toxicity, or alopecia. Mylotarg is an effective treatment for older patients with CD33-positive AML in first relapse and has acceptable toxicity.
Introduction
The incidence of acute myeloid leukemia (AML) increases with age and is five per 100 000 at age 60 and 17 per 100 000 at age 80. 1 The median age of the total AML patient population is 62 to 64 years at initial presentation. 2 Older patients with AML have a poorer treatment outcome than younger patients. When patients aged 60 years and older with newly diagnosed AML undergo induction chemotherapy, complete remission (CR) rates of 40% to 60% are generally obtained with disease-free survival less than 20% at 3 years. [3] [4] [5] [6] [7] In contrast, patients younger than 60 years have CR rates of 70% to 80% with disease-free survival up to 40% at 5 years. 5, 6 Patients who relapse have a poor prognosis. After additional chemotherapy, patients aged 60 years and older have had second remission rates of 14% to 76% and patients younger than 60 years have had second remission rates of 33% to 69%. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Older patients with AML are thought to have a poorer outcome than younger patients with AML because of biological differences in the disease and because of the inability of older patients to tolerate more intensive antileukemic therapies. The disease in older patients commonly evolves from previous hematologic disorders, such as myelodysplastic syndromes, which are often refractory to therapy. Older AML patients have a higher incidence of poor-risk cytogenetic abnormalities and expression of the multidrug resistance phenotype. 5, [18] [19] [20] In addition, older patients tolerate intensive chemotherapy poorly because of comorbid conditions and the decreased ability to tolerate myelosuppression. Thus, treatment outcome is poor in older patients with AML, and for many, the goal is palliation of symptoms rather than cure.
A less toxic therapy for older patients with AML would be of great benefit. Antibody-targeted chemotherapy is expected to be less toxic than conventional chemotherapy and has been developed for the treatment of CD33-positive AML. The antibody-targeted chemotherapy Mylotarg (gemtuzumab ozogamicin, Wyeth Laboratories, Philadelphia, PA, USA) consists of a humanized anti-CD33 monoclonal antibody conjugated to calicheamicin, a highly potent antitumor antibiotic that cleaves double-stranded DNA at specific sequences. 21 Approximately 90% of AML patients have myeloid blast cells that express the CD33 surface antigen. [22] [23] [24] This antigen is present on normal hematopoietic progenitor cells but not on normal hematopoietic stem cells or on nonhematopoietic cells. 25 It also is present on the leukemic stem cells of at least some AML patients. 26 Thus, Mylotarg is targeted treatment for patients with CD33-positive AML because the antibody component of the molecule targets calicheamicin, the cytotoxic component, to CD33-positive cells.
In a phase I dose-escalation trial with relapsed or refractory CD33-positive AML patients, eight of 40 (20%) patients treated with Mylotarg had leukemic blast cells eliminated from the blood and marrow. 27 In phase II efficacy and safety trials, a preliminary report indicated that 42 of 142 (30%) patients with AML in first relapse obtained remission after treatment with two doses of Mylotarg at 9 mg/m 2 . 28 Although severe myelosuppression was common, mucositis and severe infections were not. Based on these data, Mylotarg was approved in the United States for the treatment of patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Here, we specifically report data from the phase II trials on the efficacy and safety of Mylotarg in patients Ն60 years of age for whom it was approved. These results show that Mylotarg, as a single agent, offers an effective, well-tolerated treatment option for older patients with AML in first relapse. These 101 older patients were included among the 188 adult patients of all ages who were enrolled on the phase II clinical trials. 29 Limited data on 80 of these older patients were included in an earlier report on the first 142 patients who were treated.
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Patients and methods
Patients
A total of 101 patients Ն60 years of age with CD33-positive AML in first relapse were evaluated for the efficacy and safety of Mylotarg as a monotherapy. The diagnosis of CD33-positive AML was confirmed at relapse by analysis of bone marrow aspirates and immunophenotyping. 28, 30 Patients had CD33-positive AML if greater than 80% of leukemic blast cells displayed CD33 immunofluorescence four times above background staining when assayed in either of two central laboratories.
Patients with CD33-positive AML in untreated first relapse were enrolled on one of three similar open-label, single-arm, multicenter studies in which Mylotarg could be administered in either outpatient or inpatient settings. In two of the studies, one conducted in the United States and Canada and one conducted in Europe, patients were required to be Ն18 years of age and to have had a first remission of Ն6 months. In the third study, conducted in the United States and Europe, patients were required to be Ն60 years of age and to have had a first remission of Ն3 months. In the study conducted in Europe only, prior hematopoietic stem cell transplantation (HSCT) during first remission was permitted, and one older patient with prior HSCT was enrolled. In all three studies, patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, no antecedent hematologic disorder preceding initial presentation with AML, no therapy-related AML, normal renal and liver function, and peripheral white blood cell (WBC) counts of less than 30 000/l. Hydroxyurea treatment was recommended to reduce peripheral WBC counts to less than 30 000/l to decrease the likelihood of causing pulmonary leukostasis because of administration of an antibody to patients with very high peripheral WBC counts. Enrollment for the patients reported here was from 12 May 1997 to 5 August 1999.
Because all patients were enrolled on these three studies using similar criteria and were treated with Mylotarg in the same way, the data obtained were combined to maximize the number of patients available for analysis.
Cytogenetic analyses were performed on 60 (59%) of the 101 patients at the time of first relapse. 
Mylotarg dosage
Mylotarg was administered to patients as a 2-hour intravenous infusion at a dose of 9 mg/m 2 for two doses with at least 14 days, but no more than 28 days, between doses. Patients were required to remain under close medical supervision for an additional 6 h after the infusion irrespective of outpatient or inpatient therapy. Prior to administration, patients were required to have peripheral WBC counts of less than 30 000/l. Patients received a second dose of Mylotarg if they had recovered from nonhematologic toxicities due to the previous treatment and had no evidence of uncontrolled infection, disease progression, or detectable formation of antibodies reactive with the drug. Hematopoietic growth factors were not routinely used.
Patients could receive a third dose of Mylotarg if they did not achieve remission after two doses and if they met specific criteria. They had to meet all the criteria required for a second dose. A bone marrow aspirate performed after the second dose had to indicate Ͼ50% decrease in the percentage of bone marrow blasts compared with the screening bone marrow aspirate, and a bone marrow biopsy had to indicate Ͼ15% cellularity. Patients were permitted to receive additional chemotherapy or HSCT after completion of all planned Mylotarg therapy.
Efficacy assessments
The outcomes of patients were evaluated for two time periods -the treatment phase and the follow-up phase. The treatment phase was the time from the first dose of Mylotarg until 28 days after the last dose. The follow-up phase continued until death or the data cutoff date on 31 March 2000.
The primary assessment of efficacy was the rate of remission. There were two categories of remission -complete remission (CR) and complete remission with incomplete platelet recovery (CRp). Patients with CR had no leukemic blast cells in the peripheral blood, Յ5% leukemic blast cells in the bone marrow as measured by either bone marrow aspirate or biopsy; peripheral blood values of hemoglobin Ն9 g/dl, absolute neutrophil counts (ANC) Ն1500/l, and platelet counts Ն100 000/l; red blood cell transfusion independence for Ն2 weeks; and platelet transfusion independence for Ն1 week. Patients with CRp met the same remission criteria as those with CR except that there was incomplete recovery of platelets to 100 000/l at the time of assessment. However, patients with CRp could later be evaluated as having achieved CR based on subsequent blood counts. Both groups were required to have platelet transfusion independence. Patients who had Յ5% bone marrow blasts at the end of the treatment phase were followed with complete blood counts (CBC) during the follow-up phase to document hematopoietic recovery. All marrow aspirates and biopsies were coded and reviewed by an experienced reviewer (JMB) who was blinded to treatment outcome. The CR and CRp remission rates were combined to give an overall remission rate. Patients were considered to have no remission if they did not meet all the criteria for CR or CRp.
Efficacy assessments also included relapse-free survival and survival. Relapse-free survival was measured from the date of first documentation of remission to the date of relapse, death, or data cutoff. Survival was measured from the date of administration of the first dose of Mylotarg until the date of death or data cutoff. Survival data were evaluated using KaplanMeier estimates.
Treatment-emergent adverse events
Treatment-emergent adverse events (TEAEs) were events that occurred or worsened during the treatment phase. Adverse events were evaluated based on the US National Cancer Institute Common Toxicity Criteria, version 1. Events with a severity of grade 1 or 2 were considered to be mild or moderate and easily manageable. Grade 3 or 4 events were considered to be severe.
Analysis for antibodies directed against components of Mylotarg
Mylotarg contains three components: the humanized monoclonal antibody hP67.6 against the CD33 antigen, a calicheamicin derivative, and a linker that joins the antibody to the calicheamicin derivative. Patients could potentially produce antibodies against hP67.6 as well as against the linker-calicheamicin complex. Blood samples were taken from patients before Mylotarg administration and on days 8 and 22 after each dose to screen for antibodies directed against hP67.6 and the linker-calicheamicin complex. Serum was analyzed using enzyme-linked immunosorbent assays (ELISAs). A post-dose sample was considered positive for antibodies to hP67.6 or the linker-calicheamicin complex if the optical density value in the ELISA was Ն10 times the value of the predose sample.
Results
Patient characteristics
A total of 101 patients Ն60 years old with AML in first relapse was enrolled on these phase II studies. Patient characteristics are shown in Table 1 . The median age was 69 years (range, 60 to 87 years). The median duration of first remission before Mylotarg treatment was 10.6 months (range, 2.2 to 73.5 months).
Prior to Mylotarg treatment, most of these older patients had been treated aggressively during their first remission to prevent relapse; 93% had received postremission therapy. Of those, 44% received intermediate-or high-dose cytarabine therapy (cytarabine Ն0.5 g/m 2 per dose). The number of courses of postremission chemotherapy varied from 0 to 11 with two cycles as the median. At the time of first relapse, 60 patients had a cytogenetic evaluation. Based on this analysis, one patient (1/60, 2%) was in the favorable-risk group, 32 patients (32/60, 53%) were in the intermediate-risk group, and 27 patients (27/60, 45%) were in the poor-risk group (Table 1) .
Leukemia
Treatment outcome
Of the 101 older patients enrolled on the phase II studies, 77 received the recommended two doses of Mylotarg, 20 received only one dose, and four received three doses. Twelve patients received only one dose of Mylotarg because of disease progression, and eight patients received only one dose because of adverse events that included infection (n = 3), bleeding (n = 2), bradycardia/hyperkalemia (n = 1), diffuse fluid retention (n = 1), and tonic/clonic seizure (n = 1). The overall remission rate for the 101 older patients treated with Mylotarg was 28% (28/101; 95% confidence interval (CI), 19% to 38%, Table 2 ). The CR and CRp remission rates were 13% and 15%, respectively. The median time to remission for the 13 CR patients was 65 days (95% CI, 50 to 99 days) and 75 days for the 15 CRp patients (95% CI, 65 to 84 days).
Twenty-five percent (25/101) of patients had Յ5% leukemic blast cells in bone marrow aspirates taken at 5 to 11 days after the first dose of Mylotarg based on analysis by an experienced central reviewer. These 25 patients included 11 who eventually had remission and 14 who had no remission (NR, Table  3 ). The 14 NR patients died from disease progression during the treatment period (n = 9) or the follow-up period (n = 5). Five remission patients had Ͼ20% to 100% blast cells in bone marrow aspirates taken at 5 to 11 days after the first dose of Mylotarg (Table 3) .
Of the four patients who received three doses of Mylotarg, two had Յ5% blasts in the bone marrow after the third dose, and one of those achieved CRp.
The effect of duration of first complete remission (CR1) was evaluated for patients treated with Mylotarg. The overall remission rate of patients having a CR1 lasting 3 to 6 months was 10% (2/21), Ͼ6 months but Ͻ12 months was 26% (10/39), and Ն12 months was 39% (16/41). The remission rate of patients with a CR1 of 3 to 6 months was statistically different from the remission rate of patients with a CR1 Ն12 months (P = 0.019). Thus, these results suggest a trend of increased remission rate with increased duration of CR1. 
1 (6) 11 (24) OR, overall remission; NR, no remission. a Of the 28 remission patients, 12 were not included in this analysis because bone marrow aspirates taken at 5 and 11 days after the first dose were not available (n = 2) or were not evaluated by the central reviewer (n = 10). b Of the 73 nonremission patients, 28 were not included in this analysis because bone marrow aspirates taken at 5 to 11 days after the first dose were not available (n = 15) or were not evaluated by the central reviewer (n = 13). c The difference in the percentages of OR and NR patients with Յ5% blasts in bone marrow aspirates was statistically significant (P = 0.016, two-sided Fisher's exact test).
Patients in different cytogenetic risk categories were analyzed for remission response (Table 4) . No correlation was observed between a positive remission response and a specific cytogenetic risk category.
Survival characteristics of older patients
Relapse-free survival of patients who obtained CR and CRp was evaluated using Kaplan-Meier analysis (Figure 1) . The curves for the CR and CRp patient groups were similar (logrank P = 0.23). The median relapse-free survival was 6.8 months for the 13 CR patients and 2.2 months for the 15 CRp patients. When data for CR and CRp patients were combined, the median relapse-free survival was 3.3 months (95% CI, 2.3 to 6.5 months). Table 4 Remission response of patients treated with Mylotarg based on cytogenetic risk category at first relapse (n = 60) Risk group n OR, CR, CRp, NR, n (%) n (%) n (%) n (%) OR, overall remission; CR, complete remission; CRp, complete remission with incomplete platelet recovery; NR, no remission.
Figure 1
Relapse-free survival of older AML patients who obtained CR (n = 13) or CRp (n = 15) after treatment with Mylotarg. Medians were 6.8 months and 2.2 months, respectively (log-rank P = 0.23).
The median survival for all older patients enrolled on these trials was 5.4 months (95% CI, 3.8 to 7.2 months). The median survival was 14.5 months for CR patients, 11.8 months for CRp patients, and 4.1 months for NR patients (Figure 2 ). For this analysis, those who died during the treatment phase were excluded to prevent biasing the NR category by including patients who did not survive long enough to complete an evaluation for remission. The overall survival P value for comparing the three response groups using the log-rank test is 0.0001. There was no statistically significant difference detected between the CR and CRp groups (P = 0.2190), but Survival of older AML patients who had CR, CRp or NR after treatment with Mylotarg. Thirteen patients with CR, 15 patients with CRp, and 59 NR patients who were alive after the treatment phase were analyzed. The medians were 14.5 months, 11.8 months and 4.1 months, respectively (overall log-rank P Ͻ 0.0001; CR vs CRp, P = 0.2190; CR vs NR, P = 0.0001; CRp vs NR, P = 0.0025).
both the CR and CRp groups were statistically significantly different from the NR group (P = 0.0001 and P = 0.0025, respectively). The probability of survival at 12 months was 0.67, 0.50 and 0.08 for CR, CRp and NR patients, respectively. Thus, CR and CRp patients survived substantially longer than NR patients.
The median survival for Mylotarg-treated patients who had had a CR1 lasting 3 to 6 months was 2.7 months, Ͼ6 months but Ͻ12 months was 4.4 months, and Ն12 months was 9.7 months.
Therapy after Mylotarg treatment
After treatment with Mylotarg, some patients had additional antileukemic chemotherapy or HSCT, or they received no additional therapy as prescribed by their physicians. Of the 28 remission patients, five had HSCT (three also had other nonpreparative antileukemic chemotherapy before HSCT), four had other antileukemic chemotherapy alone, and 19 had no further therapy. Four of the five HSCT patients had successful post-HSCT engraftment ( Table 5 ). The survival for the five patients who received HSCT ranged from 8.0 to Ͼ16.0 months, and two patients were alive at the data cutoff date. The survival for the four patients who received other antileukemic therapy alone ranged from 4.7 to Ͼ18.3 months, and two patients were alive at the data cutoff date. For the 19 patients who received no further therapy, the median survival was 11.4 months (95% CI, 10.4 to 17.6 months), and seven were alive at the data cutoff date.
Of the 73 NR patients, one received additional antileukemic chemotherapy and then an autologous HSCT, 34 received other antileukemic chemotherapy alone, and 38 received no further therapy. The patient who received HSCT did not have successful engraftment by day 100 but had a survival of 18.8 months. The median survival of the 34 NR patients who had other antileukemic chemotherapy was 4.4 months, and four patients were alive at the data cutoff date. The median survival of the 38 NR patients who received no further therapy was 2.1 months, and one patient was alive at the data cutoff date. Table 5 Survival of remission patients who received additional therapy 
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Multivariate analysis to identify prognostic factors predictive of response to Mylotarg
In an exploratory multivariate analysis, 23 variables were examined to determine their potential as prognostic factors for response of patients to Mylotarg. 28 Although preliminary, results for 77 patients suggested that the likelihood of having remission was associated with low levels of leukemic blast cells in bone marrow aspirates (P = 0.024), low levels of multidrug resistance efflux (p = 0.024), and a low ECOG performance status score (P = 0.037) immediately prior to Mylotarg administration. In addition, results for 63 patients suggested that the likelihood of having survival was associated with a long duration of CR1 (P = 0.036) and low levels of leukemic blast cells in bone marrow biopsies (P = 0.032), a low ECOG performance status score (P = 0.002), no CD34 expression (P = 0.016), and no CD56 expression (P = 0.002) immediately prior to Mylotarg administration. The level of CD33 expression and the other variables examined were not associated with the likelihood of having remission or survival (P Ͼ 0.05). These results are considered preliminary because incomplete data on some of the patients prevented them from being included in the analysis.
Two or three courses of Mylotarg therapy
Five patients received more than one course of Mylotarg therapy. To be eligible for another course of therapy, a patient had to have had a remission and had a relapse. All patients who received more than one course of Mylotarg therapy were still CD33-positive at relapse. Four patients received two courses of therapy, but none achieved a third remission. One patient who was 75 years old received three courses of ther-Leukemia apy. This patient had had a 12-month CR1 before Mylotarg treatment, relapsed, and then received a first course of Mylotarg therapy. The second remission lasted 6.5 months. Retreatment with Mylotarg resulted in a third remission lasting 9 months. On third relapse, the patient received a third course of Mylotarg, and his subsequent remission was ongoing at 4 months at the data cutoff date.
Immunogenicity of Mylotarg
None of the patients treated with one, two, or three courses of Mylotarg developed detectable antibodies to the humanized hP67.6 antibody or the linker-calicheamicin complex of the Mylotarg molecule based on the ELISA analyses described in Patients and methods.
Treatment-emergent adverse events after Mylotarg treatment
Grade 3 or 4 infusion-related nonhematologic TEAEs that occurred with an incidence of Ն4% were chills (10%), hypotension (6%) and fever (4%). These symptoms were similar to those seen with other antibody-based therapies. 32 Fever and chills occurred despite prophylactic administration of acetaminophen and diphenhydramine or other antihistamines. Hypotension occurred several hours after completion of the infusion, in some cases, and was transient and reversible with intravenous fluid administration. Patients had a lower incidence of grade 3 or 4 infusion-related TEAEs after the second dose of Mylotarg than after the first dose; 30% of patients had one or more grade 3 or 4 events after the first dose, and 10% of patients had these events after the second dose.
During the treatment phase, myelosuppression occurred in essentially all of the Mylotarg-treated patients as is typical for AML patients treated with conventional chemotherapy. The incidence of grade 3 or 4 neutropenia was 99% and that of thrombocytopenia was also 99%. For both CR and CRp patients, the median time to ANC recovery to 500/l from the first dose of Mylotarg was 42 days (Figure 3 ) and from the second dose was 22 days. Patients who received the second dose of Mylotarg 13 to 17 days after the first dose had a more rapid ANC recovery than did patients who received the
Figure 3
The time to ANC recovery to 500/l from the first dose of Mylotarg for CR and CRp patients. Thirteen CR patients and 15 CRp patients were analyzed. Medians were 42 days for both CR and CRp patients. second dose at least 18 days after the first dose. For example, for the 30 CR, CRp and NR patients who received the second dose of Mylotarg 13 to 17 days after the first dose (median = 14 days), the median time to ANC recovery to 500/l from the first dose was 37 days. For the 22 CR, CRp and NR patients who received the second dose of Mylotarg at least 18 days after the first dose (median = 25 days), the median time to ANC recovery to 500/l from the first dose was 45 days.
The time to recovery of platelet counts was longer for CRp patients than for CR patients. The median time to recovery of platelets to 25 000/l from the first dose of Mylotarg was 36 days for the 13 CR patients and 75 days for the 15 CRp patients (Figure 4 , P Ͻ0.01). The median time to recovery of platelets to 100 000/l among the 13 CR patients was 50 days (95% CI, 43 to 57 days). CRp patients had maximum platelet recoveries in second remission as follows: four with Ͼ25 000/l but Ͻ50 000/l; six with Ͼ50 000/l but Ͻ75 000/l; three with Ͼ75 000/l but Ͻ90 000/l; and two with Ͼ90 000/l but Ͻ100 000/l. Four of these CRp patients had additional therapy in second remission that precluded following their platelet counts further.
Severe bleeding (grade 3 or 4) occurred in 11% of all patients. Cerebral hemorrhage (3%) and epistaxis (3%) occurred most frequently. The incidence of severe bleeding was 0% (0/13) for CR patients, 7% (1/15) for CRp patients, and 14% (10/73) for NR patients.
Only 4% of Mylotarg-treated patients experienced grade 3 or 4 mucositis during the treatment phase. Two of these four patients had hydroxyurea treatment 2 days before administration of Mylotarg and had onset of grade 3 or 4 mucositis reported on day 8 or 15. The other two patients with severe mucositis had not been treated with hydroxyurea. The incidence of grade 3 or 4 infections was 27%. Sepsis (15%) and pneumonia (6%) were the most common infections.
Other grade 3 or 4 TEAEs reported during the treatment phase with incidences of Ն10% were fever (14%), anemia (13%), chills (13%), dyspnea (12%), hypertension (12%), nausea or vomiting (12%), and asthenia (11%). No treatmentrelated cardiotoxicity, cerebellar toxicity, or alopecia was observed.
Grade 3 or 4 hyperbilirubinemia (Ͼ1.5 times the upper limit of the normal range) occurred in 24% (24/101) of patients after the first, second, or both doses of Mylotarg. Grade 3 or 4 hyperbilirubinemia first occurred after the first dose in 58% (14/24) of patients and after the second dose in 42% (10/24)
Figure 4
The time to recovery of platelet counts to 25 000/l from the first dose of Mylotarg for CR and CRp patients. Thirteen CR patients and 15 CRp patients were analyzed. Medians were 36 days and 75 days, respectively (log-rank P Ͻ 0.01).
of patients. The median time to onset for patients with initial toxicity after the first dose was 6 days, and the median time to onset for patients with initial toxicity after the second dose was 13 days. Five (5%) patients had hyperbilirubinemia that was more than three to 10 times the upper limit of the normal range, but no patient had a bilirubin elevation that was more than 10 times the upper limit of the normal range.
Grade 3 or 4 elevations of AST or ALT (Ͼ5 times the upper limit of the normal range) were observed for 15% of patients after the first, second or both doses of Mylotarg. Grade 3 or 4 elevations of AST or ALT first occurred after the first dose in 60% (9/15) of patients and after the second dose in 40% (6/15) of patients. The median time to onset for patients with initial toxicity after both the first and second doses was 6 days. Most abnormalities of liver function were transient and reversible and required no medical intervention.
Five patients with grade 3 or 4 elevations of bilirubin or hepatic transaminase levels were also reported to have grade 1 or 2 ascites. For four patients, the ascites was reversible with a median duration of 31 days (range, 7 to 66 days). The other patient, who was 74 years of age, had ascites for a total of 130 days until he died 156 days after the first dose of Mylotarg. The patient had decreasing blood cell counts at the time of his last laboratory tests, 1 month before death. The cause of death was reported as hepatic failure.
Early death rate
Fourteen of the 101 (14%) patients died during the treatment phase. The causes of death included disease progression (n = 9), cerebral hemorrhage (n = 2), sepsis (n = 2), and infection (n = 1).
Hospitalization
Because Mylotarg has a short infusion period and few severe infusion-related TEAEs, 32% and 38% of the 101 patients received the first and second doses of Mylotarg, respectively, as outpatients; 27% (21/77) received both doses as outpatients. When patients required hospitalization during the treatment period, the median total duration was 26 days (range, 1 to 133 days); 13% of the 101 patients were hospitalized for a total of Յ7 days. The 28 patients who achieved remission had a median of 25 days in hospital (range, 0 to 71 days) compared with 26 days for the 73 NR patients (range, 0 to 133 days).
Evaluation of patients Ն70 years of age after treatment with Mylotarg
Ten of 43 (23%) patients who were Ն70 years had remission (six CR and four CRp patients; 95% CI, 12% to 39%). The median survival for the 43 patients was 4.5 months, and the mortality rate during the treatment period was 12% (5/43).
Discussion
The results reported here indicate that Mylotarg, as a monoLeukemia therapy, is an effective treatment for patients Ն60 years of age with AML in first relapse. The efficacy of Mylotarg for older patients was similar to that previously reported for younger adult patients. The overall remission rate was 28% and is comparable to the 34% overall remission rate reported for 87 adult patients younger than 60 years in the phase II clinical trials. 29 Older patients had a median survival of 5.4 months, and the 87 younger patients had a median survival of 5.9 months.
Thirteen patients had a complete remission and 15 had a complete remission with incomplete platelet recovery to 100 000/l. While the Kaplan-Meier relapse-free survival curves for these two subgroups were not statistically different, the median relapse-free survival of 6.8 months for the CR patients compared with 2.2 months for the CRp patients suggests that the outcome of Mylotarg treatment for these two groups may be different with further follow-up.
The overall remission rate and median survival for these older Mylotarg-treated patients were within the range of those obtained with conventional AML treatment regimens. In the literature, remission rates for older patients with relapsed or refractory AML ranged from 14% to 76% and median survival ranged from 3 months to 12 months. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] These broad ranges can largely be explained by differences in eligibility criteria and pretreatment prognostic factors, such as age and duration of first complete remission.
The adverse event profile of Mylotarg was consistent with its targeted nature and was different from that of conventional chemotherapies. This may offer advantages to selected older patients who cannot tolerate intensive chemotherapy. The grade 3 or 4 infusion-related adverse events reported were similar to those reported for other antibody therapies. 32 The low incidence of these events, along with the short infusion time for Mylotarg, allowed about a quarter of the patients in these studies to have both doses of Mylotarg administered as outpatients. However, outpatient administration requires an observation period after infusion of Mylotarg to identify and treat fever, hypotension, and dyspnea that can occur up to 6 h after the end of the infusion periods.
Conventional reinduction therapies commonly exclude older AML patients due to the high incidence of toxicity and treatment-related mortality. However, older AML patients treated with Mylotarg had toxicity incidences and an early death rate that were comparable to those of younger adult AML patients treated with Mylotarg. For older Mylotargtreated patients, the incidence of grade 3 or 4 mucositis was low (4%) and similar to the incidence of mucositis previously reported for the 87 younger adult patients (2%). 33 The incidence of grade 3 or 4 infections was essentially the same for the 101 older patients (27%) and the 87 younger adult patients (26%), as were the incidences of grade 3 or 4 hyperbilirubinemia (24% for older patients, 28% for younger adult patients) and grade 3 or 4 elevated hepatic transaminases (15% for older patients and 18% for younger adult patients). The early death rate for both younger adult and older AML patients was 14%.
In the literature, only two studies have reported outcomes and adverse events for series of older patients with relapsed or refractory AML. 15, 33 Each used modified, reduced induction regimens. When older patients were treated with reduced doses of high-dose cytarabine and mitoxantrone (n = 44), the incidence of grade 3 or 4 mucositis was 4%. 15 When older patients were treated with continuous-infusion daunorubicin and carboplatin (n = 15), severe mucositis was not reported. 33 For all adults with relapsed and refractory AML treated with conventional combination therapy, however, the incidence of grade 3 or 4 mucositis was as high as 34%, 43 which is higher than the 4% incidence of grade 3 or 4 mucositis for older Mylotarg-treated patients.
The occurrence of severe neutropenia and thrombocytopenia was expected based on the targeting of Mylotarg to CD33-positive myeloid progenitor cells. However, the 27% incidence of grade 3 or 4 infections for older Mylotarg-treated patients was relatively low compared with the incidences of 56% 15 and 59% 33 in the two studies of older patients treated with the modified induction regimens. Moreover, the incidence of grade 3 or 4 infections has been reported to be as high as 83% for adults with relapsed or refractory AML treated with conventional combination therapy. 44 Patients treated with Mylotarg may have a relatively low incidence of severe infections because the targeted nature of the therapy may cause only limited damage to the gastrointestinal mucosa so that these myelosuppressed patients have a lower incidence of bacteremia. This low incidence of severe infection may have contributed to the low early death rate of the older Mylotargtreated patients because infection is a major cause of early deaths in AML patients.
Treatment-related cardiac or cerebellar toxicity can occur in older populations treated with anthracyclines and cytarabine but did not occur among the older Mylotarg-treated patients. Alopecia was not observed, as would be expected for an antibody-targeted chemotherapy.
The incidences of grade 3 or 4 elevations of bilirubin (24%) and hepatic transaminases (15%) for older Mylotarg-treated patients were higher than those observed for older patients treated with the modified induction regimens (grade 3 or 4 bilirubin elevations, 8% 15 and 0%; 33 grade 3 or 4 hepatic transaminase elevations, 8% 15 and not reported 33 )). However, for all adults with relapsed or refractory AML treated with conventional combination therapies, the reported incidences of elevated bilirubin or hepatic transaminases ranged from 2% 45 to 31%. 46 The elevated levels of bilirubin and hepatic transaminases in Mylotarg-treated patients generally were transient and reversible. Clinically serious hepatic veno-occlusive disease (VOD) occurred in the phase II trials in 2% of 188 patients after Mylotarg administration with a death rate of less than 1%. 47 No cases of VOD were diagnosed in the older patients included in this study, although four patients had transient ascites and the 74-year-old patient with prolonged ascites may have had VOD.
Mylotarg, an antibody-targeted chemotherapy, provides an effective and well-tolerated treatment option for older patients with CD33-positive AML in first relapse. Unfortunately, the duration of remission is short. Further studies are required to evaluate its usefulness as primary therapy or in combination with other antileukemic agents and to determine the mechanisms of leukemia cell resistance.
